Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab phase 3b trial in active psoriatic arthritis
2020-004981-20Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab with Placebo (2 arms). Primary endpoint: Proportion of participants with American College of Rheumatology 20 response. Started May 2021; status: active.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2020-004981-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004981-20.